The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Sangamo Therapeutics has stacked up $18 million cash from Eli ... deal that will let the pharma use the biotech's neurotropic adeno-associated virus capsid in efforts to develop a gene therapy ...

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.

Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly has entered into an exclusive licence agreement worth over $620m to gain rights to QurAlis’ investigational precision therapy for neurodegenerative diseases including amyotrophic lateral ...

Eli Lilly and Creyon ... new drug candidates for Lilly’s named targets. Oligos are short DNA or RNA molecules that can be used in a number of ways. Oligo-based medicines are “an ideal modality” for ...